Extractables & Leachables
Learn about various aspects of E&L analysis like analytical methodology, regulations and standards related to pharmaceutical packaging and biomedical devices. Learn more
Learn about various aspects of E&L analysis like analytical methodology, regulations and standards related to pharmaceutical packaging and biomedical devices. Learn more
With the surge in monitoring mutagenic impurities like nitrosamines, the regulatory guidelines are also fast-evolving. Stay up-to-date with all the latest developments. Learn more
This topic will resolve your most common challenges and pain points encountered through the course of a mutagenic/nitrosamines impurities analysis workflow. Learn more
Interact with your industry peers and thought leaders through an exclusive panel discussion. Learn more
Targeted LC/MS based assessment of Extractables & Leachables in pharma
Recent trends & regulatory developments in Mutagenic/Nitrosamine impurities analysis
Address common workflow challenges during Nitrosamines analysis
Pharma Thought Leader Summit
Access the webinar at your convenience
What did the webinar cover:
Access the webinar at your convenience
What did the webinar cover:
Access the webinar at your convenience
What did the webinar cover:
Access the webinar at your convenience
What did the webinar cover:
Drug containers are meant to protect the drug from environmental contaminants. Also, as commercial biopharmaceutical manufacturing continues to increase, smaller batch size and ambient processing conditions have led to a rapid increase in single-use systems (SUS) and SUS components. However, they themselves become a source of contamination. E&Ls may be toxic or may interact with drug products, causing potential danger to patients. Product recalls due to contamination by E&Ls have a significant impact on both patients and manufacturers.
The ability to perform accurate, sensitive qualitative and quantitative analysis of extractables and leachables is an essential part of pharmaceutical manufacturing and product testing.
E&L analysis by LC/MS using both targeted and untargeted workflows is employed for screening and confirmation of known unknowns.
Improving confidence in compound identification using Agilent curated database and libraries
Screening and identification of extractables in drug containers
Automated targeted screening of leachables in pharmaceutical QC labs
On-demand webinar - Targeted LC/MS based assessment of Extractables & Leachables in pharma
Video: See how Jordi Labs addresses the challenges of accurate determination of trace unknowns in extractables and leachables (E&L) analysis (Watch Video).
Access the webinar at your convenience
Targeted LC/MS-Based Assessment of Extractables and Leachables in Pharma
Speaker: Dr. David Weil
Global Technical Leader Agilent Extractables and Leachables Analysis Project
In 2018, several ARB-class drug products were recalled due to the presence of unacceptable levels of mutagenic nitrosamine impurities. Since then, more classes of drugs have been added to the list, newer impurities are being monitored, and regulatory limits for identification and quantification are going down.
Drug manufacturing processes are being evaluated to identify and control the source of contamination in APIs and drug products.
Understanding of this evolving regulatory landscape has become critical for confident analysis and release of the drug product.
Simultaneous Quantification of Mutagenic Azido Impurity Analogues in Five Different sartan APIs and Formulations
Simultaneous Determination of Eight Nitrosamine Impurities in metformin Extended-Release Tablets
Determination of a Genotoxic NDMA Impurity in ranitidine drug substance and drug products
Case Study | A Conversation with Dr. A. Siva Lakshmi Devi of Laurus Labs
On-demand webinar - Recent trends & regulatory developments in Mutagenic/Nitrosamine impurities analysis
Access the webinar at your convenience
Recent Trends & Regulatory Developments in Mutagenic/Nitrosamine Impurities Analysis
Speaker: Chander Mani
Application Specialist, Agilent Technologies, extensive research on nitrosamine
applications
From method development to method transfer to QC, you may face certain analytical challenges and bottlenecks during Nitrosamines or Mutagenic Impurities analysis. These challenges can reduce confidence in your results and hamper workflow efficiency.
We would like to address and resolve these challenges. Please vote your most common pain-point faced during Nitrosamines workflow. The webinar will be based on your votes and your challenges.
Please select at least one option
Access the webinar at your convenience
Address Common Workflow Challenges During Nitrosamines Analysis
Speaker: Chidella-Kartheek Srinivas
Technical and Application Support Specialist, Agilent Technologies, specializes in
support for genotoxic impurity
applications
On-demand webinar - Address common workflow challenges during Nitrosamines analysis
Thought leaders are pioneers of their industry and bring valuable insights and knowledge from their rich and varied experience. This summit brings together a panel of pharma industry experts and forerunners of pharma industry to share their wisdom and engage in a stimulating discussion.
The panel discussion will address some of the key focus areas and opportunities in mutagenic impurities workflows and best practices being followed by pharma leaders.
Access the webinar at your convenience
Pharma Thought Leader Summit
On-demand webinar - Thought Leader Summit